MedTrace Logo

Policaptil Gel Retard® in Overweight and Mild Obese Subjects

NCT03423368 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2018-02-13

No results posted yet for this study

Summary

This is a randomized, double blind, placebo controlled, interventional clinical study aimed at evaluating the effects of the medical device Libramed (Policaptil Gel Retard®) on the glycemic, lipid and weight profile in overweight and mild obese subjects

Conditions

  • Overweight and Obesity

Interventions

DEVICE

Libramed

Policaptil Gel Retard

DEVICE

Placebo

Placebo-comparator

Sponsors & Collaborators

  • Sprim Advanced Life Sciences

    collaborator OTHER

  • Aboca Spa Societa' Agricola

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-26
Primary Completion
2018-01-22
Completion
2018-02-09

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03423368 on ClinicalTrials.gov